Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq futures fall as oil prices jump, key earnings loom
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
| (AMEX: MBCOF) | Delayed: 0.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.07 | 52 Week High | $ | |||
| Open | $0.07 | 52 Week Low | $ | |||
| Day High | $0.07 | P/E | N/A | |||
| Day Low | $0.07 | EPS | $ | |||
| Volume | 2 | |||||
| Marvell Technology Group Ltd (NASDAQ: MRVL) | Delayed: 237.09 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $237.09 | 52 Week High | $13.61 | |||
| Open | $237.09 | 52 Week Low | $7.40 | |||
| Day High | $237.09 | P/E | 370.45 | |||
| Day Low | $237.09 | EPS | $0.64 | |||
| Volume | 298,604 | |||||
